Columnar-lined (Barrett's) esophagus

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Barrett's esophagus can be found in 10% to 15% of patients who have endoscopic examinations because of symptomatic gastroesophageal reflux disease. For every case identified by a physician, there are approximately 20 cases in the general population that go unrecognized. Physiologic abnormalities predisposing to severe gastroesophageal reflux disease are found frequently in patients with Barrett's esophagus and include extreme lower esophageal sphincter incompetence, abnormal esophageal motility, gastric acid hypersecretion, duodenogastric reflux, and diminished esophageal pain sensitivity. The abnormal epithelium regresses infrequently, if ever, with either medical or surgical therapy, and even a successful antireflux operation does not eliminate the risk of adenocarcinoma in Barrett's esophagus. Although most cases are due to gastroesophageal reflux disease, Barrett's epithelium has been found to develop in approximately two thirds of patients who receive chronic CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy for breast cancer, presumably as a result of CMF-induced esophagitis.

Original languageEnglish (US)
Pages (from-to)557-561
Number of pages5
JournalCurrent Opinion in Gastroenterology
Volume7
Issue number4
StatePublished - 1991

Fingerprint

Barrett Esophagus
Gastroesophageal Reflux
Methotrexate
Fluorouracil
Cyclophosphamide
Duodenogastric Reflux
Lower Esophageal Sphincter
Esophagitis
Gastric Acid
Adenocarcinoma
Epithelium
Breast Neoplasms
Physicians
Drug Therapy
Pain
Population
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Columnar-lined (Barrett's) esophagus. / Spechler, S. J.

In: Current Opinion in Gastroenterology, Vol. 7, No. 4, 1991, p. 557-561.

Research output: Contribution to journalArticle

@article{9d7c76708c834f8d961f3a9678f0c2e8,
title = "Columnar-lined (Barrett's) esophagus",
abstract = "Barrett's esophagus can be found in 10{\%} to 15{\%} of patients who have endoscopic examinations because of symptomatic gastroesophageal reflux disease. For every case identified by a physician, there are approximately 20 cases in the general population that go unrecognized. Physiologic abnormalities predisposing to severe gastroesophageal reflux disease are found frequently in patients with Barrett's esophagus and include extreme lower esophageal sphincter incompetence, abnormal esophageal motility, gastric acid hypersecretion, duodenogastric reflux, and diminished esophageal pain sensitivity. The abnormal epithelium regresses infrequently, if ever, with either medical or surgical therapy, and even a successful antireflux operation does not eliminate the risk of adenocarcinoma in Barrett's esophagus. Although most cases are due to gastroesophageal reflux disease, Barrett's epithelium has been found to develop in approximately two thirds of patients who receive chronic CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy for breast cancer, presumably as a result of CMF-induced esophagitis.",
author = "Spechler, {S. J.}",
year = "1991",
language = "English (US)",
volume = "7",
pages = "557--561",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Columnar-lined (Barrett's) esophagus

AU - Spechler, S. J.

PY - 1991

Y1 - 1991

N2 - Barrett's esophagus can be found in 10% to 15% of patients who have endoscopic examinations because of symptomatic gastroesophageal reflux disease. For every case identified by a physician, there are approximately 20 cases in the general population that go unrecognized. Physiologic abnormalities predisposing to severe gastroesophageal reflux disease are found frequently in patients with Barrett's esophagus and include extreme lower esophageal sphincter incompetence, abnormal esophageal motility, gastric acid hypersecretion, duodenogastric reflux, and diminished esophageal pain sensitivity. The abnormal epithelium regresses infrequently, if ever, with either medical or surgical therapy, and even a successful antireflux operation does not eliminate the risk of adenocarcinoma in Barrett's esophagus. Although most cases are due to gastroesophageal reflux disease, Barrett's epithelium has been found to develop in approximately two thirds of patients who receive chronic CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy for breast cancer, presumably as a result of CMF-induced esophagitis.

AB - Barrett's esophagus can be found in 10% to 15% of patients who have endoscopic examinations because of symptomatic gastroesophageal reflux disease. For every case identified by a physician, there are approximately 20 cases in the general population that go unrecognized. Physiologic abnormalities predisposing to severe gastroesophageal reflux disease are found frequently in patients with Barrett's esophagus and include extreme lower esophageal sphincter incompetence, abnormal esophageal motility, gastric acid hypersecretion, duodenogastric reflux, and diminished esophageal pain sensitivity. The abnormal epithelium regresses infrequently, if ever, with either medical or surgical therapy, and even a successful antireflux operation does not eliminate the risk of adenocarcinoma in Barrett's esophagus. Although most cases are due to gastroesophageal reflux disease, Barrett's epithelium has been found to develop in approximately two thirds of patients who receive chronic CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy for breast cancer, presumably as a result of CMF-induced esophagitis.

UR - http://www.scopus.com/inward/record.url?scp=0025884735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025884735&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 557

EP - 561

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 4

ER -